SCHEMBL95224

SCHEMBL95224

[CH2]c1ccc(C(=O)Nc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.71
PTGS1 P23219 4/20 0.71
NPC1 O15118 2/20 0.70
RAB9A P51151 2/20 0.70
RORC P51449 1/20 0.69
HDAC3 O15379 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
EPHX2 P34913 2/20 0.59
TRPV4 Q9HBA0 1/20 0.58
MAPT P10636 2/20 0.57
XBP1 P17861 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
KCNQ3 O43525 1/20 0.57
KCNQ2 O43526 1/20 0.57
KCNE1 P15382 1/20 0.57
KCNQ1 P51787 1/20 0.57
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96039 1.00 TRPV1 (0.71) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL7513604 0.91 TRPV1 (0.83) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL5592648 0.85 MEN1 (0.55) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL674439 0.84 HDAC6 (0.82) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL2923145 0.84 TRPV1 (0.73) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL11730950 0.84 NPC1 (0.77) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL2064051 0.84 TRPV1 (0.73) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL15946359 0.83 TRPV1 (0.77) TRPV1PTGS1NPC1RAB9ARORC
SCHEMBL95209 0.83 LMNA (0.76) TRPV1PTGS1NPC1RAB9AMAPT
SCHEMBL96330 0.83 MAPT (0.73) PTGS1NPC1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2007119600-A9 CARBAZOLE COMPOUND OTSUKA PHARMA CO LTD (JP) 2008-05-02 WO disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
WO-2007119600-A1 CARBAZOLE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-10-25 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB TRPV1 3946/4885PTGS1 32/4885NPC1 2361/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 TRPV1 1394/4885PTGS1 192/4885NPC1 2922/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 TRPV1 1394/4885PTGS1 192/4885NPC1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.